Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors

摘要: SUMMARY EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment paradigm of non-small-cell lung cancer (NSCLC). The observation a rapid response to single-agent EGFR TKIs led discovery EGFR-activating mutations, with subsequent studies showing superior progression-free survival in treatment-naive patients mutation-positive NSCLC treated versus platinum doublets. On basis these findings it has been suggested that benefit associated TKI therapy unselected is limited subset disease. However, erlotinib, reversible TKI, shown while drug relatively low rate wild-type tumors there evidence suggest positive impact on survival. Evidence supporting clinical erlotinib discussed this review.